Orphan drug market access, Marketing & Sales services in PL, HU, CZ, SK

Orphan drug market access, Marketing & Sales services in PL, HU, CZ, SK

  • Local in-country market research and data analysis

We research the local market - without relaying on simple extrapolations - for disease incidences and prevalence figures, talk to doctors, KOLs and patient organizations to gauge opportunities for your product.

  • Development of market access & pricing strategy plan

We develop market access plans including the possibility of named patient imports and give you a clear guidance how the market can be accessed and when patients could get on paid treatment. We check product price sensitivity taking local financial rules and regulations into account.

  • Local regulatory affairs

We make sure that your products comply with local requirements, add labeling and information leaflets if appropriate.

  • Health Technology Assessment (HTA) & reimbursement preparation

We compile the country specific, local language based reimbursement documentation and adapt value dossiers to fit regional HTA rules and requirements.

  • Named Patient Import evaluation

We provide scientific liaison services and negotiate a patient-by-patient access with National Health Insurance Funds in collaboration with medical prescribers.  Usually the product must be registered in at least one Western style country in order to start named patient imports and get a named patient financed access granted.

  • Patient finding campaigns

We organize awareness campaigns where appropriate and work with the local medical community to find and identify new patients suitable for niche and orphan drugs therapeutic approaches. Our teams gained a reputation to be a reliable and helpful partner. Pharmacenter helps to find rare disease patients for phase 2/phase 3 studies leveraging our Eastern European network of partners, rare disease KOLs and treatment centers.

  • Marketing & Sales of Orphan Drugs

Our country managers have been working formerly for orphan drug and pharmaceutical companies like Shire, SOBI, AstraZeneca and have a proven track record in selling orphan drugs and niche products. We provide a one-stop-shop, highly efficient and cost-effective way to commercialize rare disease products.

  • Pharmacovigilance

We provide pharmacovigilance services for all countries we work in and ensure that every adverse drug reaction is collected in compliance with the local regulation. Data are archived to be accessible by the Regulatory Agencies and partner companies. We are working according to highest international industry standards and national codes of practice.

Orphan drug packaging & serialization

Orphan drug packaging & serialization

We provide packaging, EU batch release and storage solutions and work with all kinds of pharmaceutical products including the ones requiring cold chain storage and cold chain packaging. Our company has been successfully audited by major pharmaceutical industry players and we have all relevant certificates like GMP and Manufacturing Certificate in place.

Pharmacenter is well positioned to work with small niche and orphan drug batches and oncology products and cooperates for shipments with wholesalers throughout the CEE region and Western Europe.

  • Warehousing services at high security warehouse close to Budapest Airport
  • Secondary (cold chain) packaging and labelling services for pharmaceutical RX and OTC products including hormones, antibiotics and cytotoxics as well as medical devices for all EU markets
  • EU batch release by Qualified Person (QP) & EU import
  • Full serialization services according to EU guidelines
Business development & territorial reach

Business development & territorial reach

What’s your plan for Eastern Europe?

  • Are you looking for an orphan drug market access & sales partner?
  • Are you tired of researching small markets with difficult languages?
  • Are you looking for timely revenue streams without the hassle to set up your own presence?

We are here to help!

A note to the kind visitor and reader!
As a highly specialized team, we are able to make your success our primary focus. We are not the large pharma partner that cycles people through unnecessary introductions, bureaucratic formalities and foregoes developing relationships; we believe that good partnerships breed success for both sides.

This means providing you with a dedicated project manager, the complete transparency that you need, and the flexible approach for those times when your goals change midstream – in a true partner model.

Let us invite you to a great partnership for the CEE region. Our target markets are Poland, Hungary, Czech Republic, Slovakia, Hungary and the Baltic.

  • Get a free consultation from our management team
  • Receive a free market evaluation report on how your niche products will be doing in our target markets
  • Get access to a 65+ million people market via a single interface
  • Benefit from our unique experience in orphan drug market access
  • You can combine our orphan drug services on a modular basis

What we are looking for?

We are looking to partner with the following type of companies for the Eastern European EU countries Poland, Czech Republic, Slovakia, Hungary and the Baltic Region:

  • Rare or ultra rare disease companies with a single pharmaceutical product or a portfolio of products they want to commercialize with an experienced market access and sales partner. We have a special expertise in oncology, lysosomal storage and muscular diseases.
  • Companies looking for named patient services in the CEE region for niche or rare disease products
  • Companies with niche biosimilar products looking for a commercialisation partner
  • Companies looking for orphan drug and niche product importation into the European Union, orphan drug packaging also under cold chain conditions, EU batch release, product storage and serialization services.
  • Diagnostic companies working in the cancer prevention/early stage diagnostic areas